Latest Stem Cells News

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.